长药控股行政处罚落地，两个区间投资者可参与索赔

Core Viewpoint - The company *ST Changyao is focusing on becoming a leading platform in the health industry, primarily engaged in the production and sales of traditional Chinese medicine, medicinal capsules, and the wholesale of pharmaceuticals, health products, and medical devices [1][10]. Group 1: Company Overview - *ST Changyao is classified under the pharmaceutical and biological sector, specifically in traditional Chinese medicine [2][10]. - The company aims to build an integrated pharmaceutical industry chain that includes the production of traditional Chinese medicine, hollow capsules, and a medical logistics network [1]. Group 2: Financial Misconduct - On November 7, 2025, the company received a notice from the China Securities Regulatory Commission regarding suspected false reporting of financial data [2][10]. - The company reported inflated revenues for 2021, 2022, and 2023, amounting to 215.32 million, 283.74 million, and 233.63 million yuan respectively, which represented 9.12%, 17.57%, and 19.51% of the disclosed revenues for those years [5][12]. - The inflated total profits for the same years were reported as 56.40 million, 63.38 million, and 43.71 million yuan, accounting for 35.62%, 88.23%, and 6.42% of the disclosed total profits [5][12]. Group 3: Investor Compensation - Investors who purchased shares between April 28, 2022, and November 7, 2025, and sold or continued to hold them after November 8, 2025, are eligible for compensation [5][12]. - Additionally, investors who bought shares between March 30, 2019, and April 29, 2024, and sold or continued to hold them after April 30, 2024, can also participate in the compensation [9][15]. Group 4: Financial Issues and Risks - As of April 30, 2024, the company disclosed significant financial issues, including a fund occupation amounting to 179.66 million yuan, which is 92.08% of the latest audited net assets [6][14]. - The company has acknowledged internal control deficiencies regarding non-operational fund occupation by its former general manager and related parties from 2019 to 2023 [7][14].